Navigation Links
Egalet Appoints Stan Musial as CFO
Date:5/8/2013

MALVERN, Pa., May 8, 2013 /PRNewswire/ -- Egalet Ltd., a privately held specialty pharmaceutical company focused on developing safe, effective and abuse-deterrent medications, announced today the appointment of Stan Musial as chief financial officer (CFO). 

"The addition of Stan to the management team comes at a critical time as the most advanced products in Egalet's pipeline of abuse-deterrent opioids are nearing phase 3," said Bob Radie , president and CEO.  "Stan's finance experience will be invaluable as we move our pipeline through development and ultimately to the commercial market."

Stan has held senior financial management positions for both publicly-held and privately-held companies, becoming experienced in executing growth strategies, raising capital, and mergers and acquisitions.  Stan most recently spent six years as vice president of finance and administration, chief financial officer, treasurer and secretary of Prism Pharmaceuticals, a specialty pharmaceutical company, which was successfully sold to Baxter Healthcare in 2011.  Prior to joining Prism he held the position of vice president, finance, and CFO for Strategic Diagnostics, Inc. (SDIX), a publicly-held biotechnology company.  He began his career with KPMG LLP.  Stan holds an MBA in finance from Temple University and a B.S. degree in accounting from Pennsylvania State University and is a Certified Public Accountant.

"I am excited to join Egalet—a company seeking to advance its pipeline of abuse deterrent opioids by taking advantage of the expedited 505(b)(2) regulatory pathway to address the growing need for safe pain medicines," said Stan Musial

About Egalet Ltd.
Egalet Ltd. is a European-based specialty pharmaceutical company using its patented technology to produce novel therapeutics on its own and with partners.  Based on the proprietary technology, Egalet is developing a pipeline of abuse-deterrent opioids that are nearing pivotal testing.  In addition, Egalet has collaborations with pharmaceutical and biotechnology companies in the initial phase of clinical testing. 

Egalet has pioneered one of the world's first erosion-based delivery technologies to enable the controlled release of drugs through gradual erosion of a tablet.   In addition, the Egalet® technology, a novel, patented drug delivery platform, is designed to prevent easy extraction and to deter the abuse of medications via known routes of abuse, including chewing, snorting, and injecting.  The uniquely shaped, patient-friendly tablet consists of matrix and can add a shell or coat.  By altering the composition of the shell and matrix, a variety of extended-release formulations can be produced.  The technology offers a predictable and tailored pharmacokinetic profile, lacks a significant food effect and alcohol dose dumping, and can be used with a broad range of opioids and non-opioids.  Egalet has an extensive portfolio of both filed patents and patent applications to protect its inventions covering both the platform technology and specific products.  Please visit www.egalet.com for more information.

Contact:
E. Blair Schoeb 
Tel.: 917-432-9275
Email: blair@biotechcomm.com  


'/>"/>
SOURCE Egalet Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Egalet to Present at Life Sciences Europe Conference
2. Egalet Announces Issuance of U.S. Patent
3. CLAAD Selects Egalet As Top Five Technologies To Reduce Prescription Drug Abuse Honoree
4. Winner Medicals Special Committee Appoints Independent Financial Advisor and Retains Legal Counsel
5. Pro-Dex, Inc. Appoints Michael J. Berthelot Chief Executive Officer
6. Nephros Appoints John C. Houghton as President and Chief Executive Officer
7. Elsevier Appoints New President of Elsevier CPM Resource Center
8. GenWay Biotech Appoints New Vice President of Custom/OEM
9. Angeion Appoints Matthew S. Margolies as Executive Vice President - Global Sales
10. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
11. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2017)... 7, 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s ... ended June 30, 2017.  All comparisons, unless otherwise noted, are ... Second Quarter 2017 Highlights include: ... million, an increase of 3.5% Total prescriptions ... margin of 7.5% versus 7.6% Gross ...
(Date:8/4/2017)... 2017 The search for test results that ... consult has long been the goal of healthcare providers ... of the largest meeting of lab professionals and IVD ... research firm Kalorama Information.  The firm said scores of ... related supplies and software were at the American Association ...
(Date:8/3/2017)...  Opioid addiction and other drugs of abuse, blood ... threatening outcomes, were problems taken on directly as laboratory ... support them, met this week. This according to Kalorama ... of abuse, procalcitonin and acute kidney injury were key ... meeting in San Diego, CA. ...
Breaking Medicine Technology:
(Date:8/18/2017)... ... 2017 , ... “Emotions are sacred, valid, honored, encouraged. This is the memo ... Generation Mindful. To help change the mindset of parents and educators from punitive to ... the Time-In Toolkit, which launched on Kickstarter 3 weeks ago and fully funded in ...
(Date:8/18/2017)... ... August 18, 2017 , ... Alcovit, a lime-flavored beverage that ... its marketing efforts with its product now available through Jet.com. , After 25 ... The effervescent powdered drink is designed to quickly detox the body thereby avoiding alcohol-induced ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... “Our Mountains ... potent tale of a couple that grew stronger together through the faith they shared ... Faith Through Trials” is the creation of published author, Barbara J. Corcoran, a retired ...
(Date:8/18/2017)... , ... August 18, 2017 , ... “Beyond Our Imaginations: ... life. “Beyond Our Imaginations: The Infinite God” is the creation of published author, Mark ... the country. , Lawrence shares, “The problem with becoming a greater man of God ...
(Date:8/18/2017)... , ... August 18, 2017 , ... “Kingdom Mandate for ... the Kingdom. “Kingdom Mandate for Kingdom Builders” is the creation of published author, ... moved to Eastern Europe as a missionary in 1983. He spent three decades ...
Breaking Medicine News(10 mins):